Abstract
This editorial focuses on male contraception and explains the current status after a multi-center contraceptive efficacy clinical trial in China that tested injectable testosterone undecanoate (TU) in 1045 healthy Chinese men over a 30 month period. It discusses how TU was terminated due to side effects that outweighed potential benefits and touches on other major developments in the field of male contraception that lie outside of the hormonal-based approach.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
